Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Completed Phase 1 Interventional

Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe

NCT00127296
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
FlexPen®, vial and syringe
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 30, 2026, 8:03 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273
View directory record Official record
Conditions
Bipolar Disorder Type I With Mania
Interventions
KarXT, Lithium, Valproate, Lamotrigine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
61
States / cities
Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 8:03 PM EDT
Terminated Early Phase 1 Interventional

Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery

NCT04630886
View directory record Official record
Conditions
Skin Neoplasms
Interventions
Tranexamic acid injection, Lidocaine Epinephrine
Drug
Lead sponsor
Riley McLean
Other
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

NCT00070070
View directory record Official record
Conditions
Transitional Cell Carcinoma
Interventions
TICE®-strain BCG, NY-ESO-1 protein, sargramostim
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 30, 2026, 8:03 PM EDT
Terminated Phase 2 Interventional Results available

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

NCT00057954
View directory record Official record
Conditions
Lymphoma
Interventions
Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX)
Procedure · Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional

Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep

NCT01901510
View directory record Official record
Conditions
Colonic Polyps
Interventions
Chromoendoscopy (Indigo Carmine), Control
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 30, 2026, 8:03 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man

NCT01634646
View directory record Official record
Conditions
Overweight, Elevated Cholesterol
Interventions
Lyzme5
Dietary Supplement
Lead sponsor
Jeff Golini
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Billings, Montana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 30, 2026, 8:03 PM EDT
Terminated Phase 4 Interventional Results available

Using Saline for Myofascial Pain Syndromes (USAMPS)

NCT02120261
View directory record Official record
Conditions
Myofascial Pain Syndrome
Interventions
Normal Saline, Lidocaine Hydrochloride, Triamcinolone acetonide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

NCT00502203
View directory record Official record
Conditions
Mixed Tumor, Mullerian
Interventions
Carboplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
4
States / cities
Loma Linda, California • Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Not applicable Interventional Results available

Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

NCT00534118
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
donor lymphocytes
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 76 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 30, 2026, 8:03 PM EDT
Terminated No phase listed Observational

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00957736
View directory record Official record
Conditions
Cancer
Interventions
polymorphism analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 30, 2026, 8:03 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis

NCT03607175
View directory record Official record
Conditions
Chronic Rhinosinusitis, Nasal Polyps
Interventions
Triamcinolone-impregnated CMC foam, Propel Stent
Drug · Device
Lead sponsor
Marina Boruk
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 4 Interventional

Dexamethasone and Post-tonsillectomy Pain in Children

NCT02793011
View directory record Official record
Conditions
Pediatric Post-tonsillectomy Pain
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 17 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 30, 2026, 8:03 PM EDT
Completed No phase listed Observational

Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

NCT02847130
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia, Childhood Burkitt Lymphoma, Childhood Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
Informational Intervention, Interview, Medical Chart Review, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
31
States / cities
Oakland, California • Wilmington, Delaware • Fort Myers, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Medifast 5 & 1 Plan

NCT01211301
View directory record Official record
Conditions
Obesity, Body Weight, Weight Loss, Overweight, Nutrition Disorders
Interventions
Food-based, Reduced Energy Diet Plan, Medifast 5 & 1 Plan
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

NCT00002663
View directory record Official record
Conditions
EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Interventions
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Biological
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers

NCT04204772
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
Activated charcoal and Tap Water, Activated Charcoal and Apple Juice
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

NCT04877366
View directory record Official record
Conditions
Dietary Supplement
Interventions
Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
Dietary Supplement · Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Intestinal Permeability 4 Hours After Gluten Challenge

NCT03288831
View directory record Official record
Conditions
Celiac Disease, Wheat Hypersensitivity, Gluten Sensitivity, Gluten Enteropathy, Immune System and Related Disorders, Duodenal Diseases
Interventions
Gluten, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional

A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas

NCT00080054
View directory record Official record
Conditions
Glioma, Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Neoplasm
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 30, 2026, 8:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurobehavioral Changes Following Spaceflight Stressors

NCT07293494
View directory record Official record
Conditions
Stressor, Individual, Alcohol Impairment, Sleep Deprivation, Impairment, Cognitive
Interventions
Alcohol Administration, Sleep Deprivation, Control
Other · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 8:03 PM EDT
Terminated Phase 1 Interventional Results available

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

NCT01285102
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors

NCT00003478
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
conventional surgery, iodine I 131 monoclonal antibody 81C6, radiation therapy
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 30, 2026, 8:03 PM EDT